Keytruda Shows Meaningful Clinical Benefit When Combined with Standard Therapy for Aggressive Breast Cancer

Keytruda Shows Meaningful Clinical Benefit When Combined with Standard Therapy for Aggressive Breast Cancer
Two independent studies have added new evidence to the benefits of combined therapies with Merck‘s PD-1 inhibitor Keytruda (pembrolizumab) for the treatment of aggressive triple-negative breast cancer (TNBC). Adding Keytruda to standard therapies for breast cancer improved the number of patients achieving a complete response to therapy. The findings will be featured in a poster, “Efficacy/safety of epacadostat plus

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *